Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018
- Oral presentation to feature preclinical data on novel core inhibitor EP-027367 targeting
hepatitis B virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s wholly-owned development programs,
including EP-027367, one of Enanta’s novel core inhibitors in preclinical testing for hepatitis B virus (HBV), and EDP-305, an FXR
agonist in development for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), have been accepted for
presentation at The International Liver Congress™ (ILC) 2018, April 11-15, in Paris, France.
EP-027367, one of several core inhibitors Enanta is evaluating, has been selected for an oral presentation. There will also be
three posters on EDP-305, which is currently in a Phase 2 study for NASH and a Phase 2 study for PBC. The U.S. Food and Drug
Administration has granted EDP-305 Fast Track designation for the treatment of NASH patients with liver fibrosis and Fast Track
designation for the treatment of patients with PBC.
In addition, several abstracts from AbbVie will be presented on their HCV regimens containing glecaprevir/pibrentasvir and
marketed under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.). Glecaprevir is Enanta’s second protease inhibitor discovered
and commercialized through its protease inhibitor collaboration with AbbVie.
The full ILC 2018 scientific program as well as the abstracts can be found at http://ilc-congress.eu/. Further details will be available at the time of these presentations.
Oral Presentation:
- Thursday, April 12, 17:45 - 18:00 CET
PS-032 - “Discovery of a novel HBV core inhibitor EP-027367 with potent antiviral activity both in vitro and in a
humanized mouse model” (M.Vaine, S.Clugston, J.Kass, X. Gao, H. Cao, W. Li, X. Peng, L.J. Jiang, K. Daniels, Y. Qiu, Y.S. Or,
K. Lin)
Poster Presentations
Thursday, April 12, 09:00 - 17:00 CET
- THU-469 - “EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory
mechanisms” (M. Roqueta-Rivera, M.D. Chau, K. Garlick, Y. Li, G. Wang, Y.S. Or, and L.J. Jiang)
Friday, April 13, 09:00 - 17:00 CET
- FRI-084 - “EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates
the expression of key fibrogenic genes in vitro and in vivo” (Y. Li, J.Y. Shang, M.D. Chau, M. Roqueta-Rivera,
K. Garlick, P. An, K. Vaid, G. Wang, Y. Popov, Y. S. Or, and L. J. Jiang)
- FRI-489 - “Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive
NAFLD subjects” (A. Ahmad, K. Sanderson, D. Dickerson, N. Adda)
About Enanta
Enanta Pharmaceuticals has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the
discovery of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir
and paritaprevir, discovered and developed through Enanta’s collaboration with AbbVie, have now been approved in jurisdictions
around the world as part of AbbVie’s direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection,
including the regimens marketed as MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) and VIEKIRAX® (paritaprevir/ritonavir/ombitasvir) (ex-U.S.).
Royalties from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently
focused on the following disease targets: non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), respiratory
syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for continuing royalties
from the AbbVie collaboration and the prospects for Enanta’s further development of EDP-305 and EP-027367. Statements that are not
historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and
the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not
guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: the marketing and commercialization efforts of others with respect to
treatment regimens for HCV that are competitive with MAVYRET/MAVIRET; regulatory and reimbursement actions affecting
MAVYRET/MAVIRET, any competitive regimen, or both; the development risks of Enanta’s early stage discovery efforts in NASH, PBC,
RSV and HBV; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key
scientific personnel; the need to obtain and maintain patent protection for glecaprevir and Enanta’s other product candidates and
avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in
“Risk Factors” in Enanta’s most recent Form 10-Q for the fiscal quarter ended December 31, 2017 and other periodic reports filed
more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta
undertakes no obligation to update or revise these statements, except as may be required by law.
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180328005548/en/